GTC Biotherapeutics (fka GTCB)

[RufusT]

"Our focus is on a group of monoclonal antibodies which are coming off patent over the next six to eight years. We have identified four or five of these products which today have a combined market of approximately $16 billion and are expected to double to approximately $30 billion over the next five or six years [#msg-20699044, item 02]."

The four or five mabs coming off patent I take it are Rituxan (targeted by the CD20 project), Avastin and other cancer mabs?